APA (7th ed.) Citation

Pflug, N., & Zenz, T. (2014). Induction treatment with alemtuzumab combined with polychemotherapy containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) followed by Alemtuzumab maintenance in patients with T-Cell prolymphocytic leukaemia (T-PLL): First analysis of a prospective multicenter phase-II-trial (T-PLL2) conducted by the German CLL study group (GCLLSG). Blood, 124(21), .

Chicago Style (17th ed.) Citation

Pflug, Natali, and Thorsten Zenz. "Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed by Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-trial (T-PLL2) Conducted by the German CLL Study Group (GCLLSG)." Blood 124, no. 21 (2014).

MLA (9th ed.) Citation

Pflug, Natali, and Thorsten Zenz. "Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed by Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-trial (T-PLL2) Conducted by the German CLL Study Group (GCLLSG)." Blood, vol. 124, no. 21, 2014.